Key result
This protocol outlines an umbrella review to evaluate the efficacy and safety of extending dual antiplatelet therapy beyond 12 months following percutaneous coronary intervention; no results are reported.
Why the study?
Does extended DAPT beyond 12 months reduce mortality compared to short-term DAPT in patients following PCI with stenting?
Systematic Review
Does extended DAPT beyond 12 months reduce mortality compared to short-term DAPT in patients following PCI with stenting?
This protocol outlines an umbrella review to evaluate the benefits and harms of extending DAPT beyond 12 months following PCI with stenting.
Answers are grounded in this paper and cite their sources.
Optimal DAPT duration after PCI remains uncertain; this protocol for an umbrella review leaves open questions on efficacy and safety beyond 12 months.
INTRODUCTION: Although dual antiplatelet therapy (DAPT) is routinely given to patients after percutaneous coronary intervention (PCI) with stenting, the optimal duration is unknown. Recent evidence indicates there may be benefits in extending the duration beyond 12 months but such decisions may increase the risk of bleeding. Our objective is to provide a comprehensive overview of the literature for clinicians and policymakers via an umbrella review assessing the optimal duration of DAPT. METHODS AND ANALYSIS: We will perform a comprehensive search of the published and grey literature for systematic reviews involving randomised controlled trials (RCTs) assessing the optimal duration of DAPT following PCI with stenting. The intervention of interest is extended DAPT (beyond 12 months) compared with short-term DAPT (6-12 months). Studies will be selected for inclusion by two reviewers, and the quality will be assessed. The primary outcomes of interest are all-cause mortality and cardiovascular mortality. Secondary outcomes will be bleeding (major, minor and gastrointestinal), urgent target vessel revascularisation, major adverse cardiovascular events, myocardial infarction, stroke and stent thrombosis. Outcomes will be assessed while on DAPT and after withdrawal of DAPT. Data will be summarised with respect to the number of included RCTs, number of participants, effect estimates and heterogeneity. Data will be reported separately based on patient demographics, procedural parameters (eg, stent types, lesion complexity and concurrent disease) and clinical presentation (eg, acute coronary syndromes, infarct type). ETHICS AND DISSEMINATION: Our umbrella review aims to provide a comprehensive overview of the benefits and harms associated with extending DAPT beyond 12 months following PCI with stenting. The results of this review will inform clinical and policy decisions regarding the optimal treatment duration and reimbursement of DAPT following PCI with stenting. Results will be disseminated through a peer-reviewed publication and conference presentations. Ethics approval is not required for this study. TRIAL REGISTRATION NUMBER: CRD42016047735.
No takes yet. Share an insight, caveat, or question.
Elliott et al. (2017) conducted a systematic review in Percutaneous coronary intervention (PCI) with stenting. Extended dual antiplatelet therapy vs. Short-term dual antiplatelet therapy was evaluated on All-cause mortality and cardiovascular mortality. This protocol outlines an umbrella review to evaluate the efficacy and safety of extending dual antiplatelet therapy beyond 12 months following percutaneous coronary intervention; no results are reported.
Synapse has enriched 10 related papers. Consider them for comparative context: